(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

Press release: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Commentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox

Commentary on Twitter (thread – click for more)

Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9

— Eric Feigl-Ding (@DrEricDing) June 14, 2021